Search
Search Results
##search.searchResults.foundPlural##
-
RELIABILITY OF DIFFERENT RBC INDICES AND FORMULAS IN DISCRIMINATING BETWEEN ?-THALASSEMIA MINOR AND OTHER CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA
2056PDF: 1644HTML: 14651Untitled: 215Untitled: 181 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2222PDF: 1176HTML: 2595Study of serum haptoglobin level in thalassemia: 350Figures: 183 -
GENETIC HETEROGENEITY OF BETA GLOBIN MUTATIONS AMONG ASIAN-INDIANS AND IMPORTANCE IN GENETIC COUNSELLING AND DIAGNOSIS
1776PDF: 1295HTML: 11519Figure1: 177Figure 2: 180 -
HEMOGLOBIN ANALYSIS IN THE FIRST YEAR OF LIFE
3509PDF: 1039HTML: 3053 -
EXERCISE STRESS ECHOCARDIOGRAPHY WITH TISSUE DOPPLER IMAGING (TDI) DETECTS EARLY SYSTOLIC DYSFUNCTION IN BETA-THALASSEMIA MAJOR PATIENTS WITHOUT CARDIAC IRON OVERLOAD
1345PDF: 815HTML: 7874Manuscript after revision: 244Barbero10328-36310-after revision: 236 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
394PDF: 353Suppl. Files: 52HTML: 19 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1331PDF: 876HTML: 1035Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 181 -
A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia
2937PDF: 1352HTML: 161 -
QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA IN KERMAN-IRAN (I.R.)
1689PDF: 768HTML: 2344Cover Letter: 189 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
88PDF: 67HTML: 12 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3962PDF: 1125HTML: 460 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2687PDF: 840HTML: 14967Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 321 -
GLUCOSE METABOLISM AND INSULIN RESPONSE TO ORAL GLUCOSE TOLERANCE TEST (OGTT) IN PREPUBERTAL PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (TDT): A LONG-TERM RETROSPECTIVE ANALYSIS Long-term retrospective analysis of glucose homeostasis in children with transfusion dependent β-thalassemia
1756PDF: 553HTML: 167 -
-
-
COMPARATIVE STUDY ON THE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA PATIENTS AND THE CLINICAL GRADING OF LIVER IRON CONCENTRATION BY DIFFERENT POST-PROCESSING SOFTWARE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA
870PDF: 614HTML: 211 -
-
-
Identification of Alpha Thalassemia, RNF 213 p.R4810K and PROC p.R189W among Children with Moyamoya Disease/Syndrome Alpha Thalassemia and RNF 213 Gene Mutation in Moyamoya
980PDF: 728HTML: 239 -
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1129PDF: 488HTML: 8185 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
2182PDF: 1317Html: 302 -
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2743PDF: 1091HTML: 2581 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
638PDF: 521Html: 109 -
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2284PDF: 619Suppl. Files: 286HTML: 176 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRASFUSION DEPENDEND-β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATION Challenges in Supportive Care, Equity, and Compassion at End of Life
1052PDF: 725Html: 161 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2573PDF: 1212HTML: 11809







